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ABSTRACT
Introduction Atrial fibrillation (AF) is the most common 
cardiac arrhythmia in critically ill patients and is associated 
with an increased risk of thromboembolic events and 
mortality. Oral anticoagulation for thromboembolism 
prophylaxis is a key component of managing AF in the 
general population and is recommended by National 
Institute for Health and Care Excellence guidelines. 
However, assessment tools used to aid decision making 
about anticoagulation have not yet been validated in the 
critical care setting. There is a paucity of data assessing 
the impact of anticoagulation strategies on clinical 
outcomes in critically ill patients with AF. We present a 
protocol for a systematic review and meta- analysis to 
evaluate the effectiveness of anticoagulation strategies for 
AF used specifically in critical care.
Methods and analysis We will conduct a systematic 
review of the literature by searching MEDLINE, EMBASE, 
CENTRAL and PubMed databases for articles published 
from January 1990 to October 2019. Studies reporting 
anticoagulation strategies for AF in adults (>18 years) 
admitted to a general critical care setting will be 
assessed for inclusion. Outcomes of interest will include 
(1) percentage of patients started on anticoagulation in 
critical care for AF, (2) incidence of thromboembolism, (3) 
incidence of bleeding events, (4) intensive care unit (ICU) 
mortality, (5) hospital mortality, (6) ICU length of stay and 
(7) hospital length of stay. We will conduct a meta- analysis 
of trials. Risk of bias will be assessed using the Cochrane 
Risk of Bias tool for randomised trials or the Newcastle- 
Ottawa Risk of Bias assessment tool for non- randomised 
studies. This protocol and subsequent systematic review 
will be reported following the Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses checklist.
Ethics and dissemination This proposed systematic 
review will include data extracted from published studies; 
therefore, ethical approval is not required. The results of 
this review will be published in clinical specialty journals 
and presented at international meetings and conferences.
Trial registration number CRD42020158237.
INTRODUCTION
Background
Atrial fibrillation (AF) is the most common 
cardiac arrhythmia in the critical care 
population. AF is characterised by erratic 
conduction of electrical impulses and unco-
ordinated contraction of the atria which 
ultimately increases the risk of heart failure, 
stroke and death.1 2 The reported incidence 
of new- onset AF (NOAF) in critically unwell 
patients admitted to intensive care unit 
(ICU) has been estimated to be between 
1.8% and 10%.1 However, a more recent 
study reported NOAF in 418 of 1782 (23%) 
of patients admitted to ICU and was associ-
ated with increased hospital mortality.2 3 AF 
can trigger rapid ventricular rates resulting 
in haemodynamic compromise and a loss of 
cardiac output. This may contribute to acute 
decompensation of already unstable criti-
cally ill patients and eventually lead to the 
increased morbidity and mortality associated 
with AF in critical care.2 4
In addition to the traditional risk factors for 
the development of AF, including advanced 
age, hypertension, ischaemic heart disease, 
heart failure and valvular disease that 
Strengths and limitations of this study
 ► This systematic review follows the Preferred 
Reporting Items for Systematic Review and Meta- 
Analysis Protocols guidelines.
 ► Study selection, data extraction and risk of bias as-
sessment will be performed independently by two 
researchers, ensuring that all relevant studies are 
included without personal biases.
 ► There are no language publication restrictions to this 
systematic review eliminating language bias.
 ► Non- randomised studies will be included in this 
review potentiating a high risk of bias in included 
studies.
 ► Given the particular risk for thromboembolic events 
in critically ill patients, we will only include studies 
on patients receiving anticoagulation during their 
critical care admission.
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predispose to pre- existing AF (PEAF), there are factors 
related to being critically ill that predispose patients to 
the development of NOAF.1 2 These factors include elec-
trolyte abnormalities, hypoxaemia, adrenergic overstimu-
lation, progressive autonomic dysfunction, acute systemic 
inflammation, sepsis and shock.1 2 Changes in autonomic 
activity resulting from vasopressor administration as well 
as electrolyte disturbances are frequent among criti-
cally ill patients and can lead to increased atrial ectopic 
impulses and subsequent NOAF.4 There is also evidence 
that central venous catheters induce mechanical irrita-
tion of the atria and may be a contributing factor in the 
development of NOAF.1 The high incidence of NOAF in 
critical care is likely due to a combination of these tradi-
tional and critical illness specific related risk factors.4
Both PEAF and NOAF are associated with a myriad of 
complications in critical care. As a result of inefficient 
atrial systole, the reduced blood flow velocity in the left 
atria predisposes patients with AF to cardiac and systemic 
emboli.5 Embolic events, such as ischaemic stroke, are 
common and disabling complications of AF and cause a 
significant disease burden.6 AF in the critical care setting 
is associated with a twofold increased risk of stroke and a 
twofold to fivefold increased risk of mortality.2 7
Oral anticoagulation for thromboembolism prophylaxis 
is a key component of managing AF in the general popula-
tion.8 In the UK, clinicians are guided in the management 
of NOAF by the recommendations from the National Insti-
tute for Health and Care Excellence (NICE). With regard 
to anticoagulation for NOAF, NICE recommends the use of 
validated tools assessing thromboembolic risk (eg, CHA2DS2- 
VASc) and bleeding risk (eg, HASBLED) to stratify patients 
that may benefit from systemic anticoagulation through 
prevention of thromboembolic events such as stroke.8 
However, the risk- benefit tools used to aid decision making 
about anticoagulation, such as the CHA2DS2- VASc and 
HASBLED scores, have not been validated in critical care 
populations.9 10 Decisions around anticoagulation strategies 
in critical care are complex and challenging. Critically unwell 
patients are at a significantly increased risk of bleeding, but 
may also of hypercoagulable, due to the abnormal haemo-
stasis that is associated with critical illness.10 Factors contrib-
uting to the acquired coagulopathy in critical care include 
severe sepsis, thrombocytopenia, haemodilution of clotting 
factors following blood transfusion, disseminated intravas-
cular coagulation, acute kidney injury and liver failure.11 The 
potential need for urgent procedures or insertion of invasive 
devices, such as arterial lines and central venous catheters, 
poses an additional challenge in effectively anticoagulating 
these patients.12 Combined with the added effect of antico-
agulation itself, the high risk of bleeding may preclude safe 
therapeutic anticoagulation for AF in critical care patients. 
Guidelines from NICE recommend anticoagulation with 
Heparin in patients presenting with NOAF that are receiving 
no or subtherapeutic anticoagulation. Furthermore, they 
recommend that patients who have failed to achieve stable 
sinus rhythm within 48 hours or have risk factors for the 
recurrence of NOAF should be offered oral anticoagulation 
long term. Despite these recommendations, a nationwide 
survey of intensive care clinicians revealed that 63.8% of clini-
cians would not routinely anticoagulate critically ill patients 
with NOAF while 30.8% would consider anticoagulation 
if NOAF persisted beyond 72 hours rather than the recom-
mended 48 hours by NICE.13 Furthermore, 98% of critical 
care clinicians revealed that they would be happy to admin-
ister Heparin as anticoagulation but not an oral anticoagula-
tion.13 The variation in practice likely represents the unique 
challenges of managing NOAF in critically unwell patients, in 
which administration of oral anticoagulants may not possible 
in sedated patients or via nasogastric tube and highlights the 
need for guidelines specific to critically ill patients.
Why is it important to undertake this review?
There is a paucity of data assessing the impact of anti-
coagulation strategies on clinical outcomes in critically 
unwell patients with AF.14 A consensus on an effective 
anticoagulation strategy for thromboembolism prophy-
laxis has not yet been reached and current recommenda-
tions regarding anticoagulation therapy are largely based 
on observational studies and expert opinion.4 We there-
fore have designed a protocol for a systematic review and 
meta- analysis of the literature around the anticoagulation 
for AF in the critically unwell and critical care setting. We 
will assess the existing literature to define anticoagula-
tion strategies in critical care for both NOAF and PEAF. 
We anticipate that the results of this review will highlight 
areas where evidence is lacking, trigger further research 
and contribute to the development of new guidelines 
specific to the management of anticoagulation in patients 
with AF in the critical care setting.
Objective
To conduct a systematic review and meta- analysis of the 
literature to determine the use and effectiveness of anti-
coagulation strategies for AF in critical care and identify 
the associated risks and benefits of therapeutic anticoag-
ulation for AF.
METHODS AND ANALYSIS
This systematic review will be conducted in accordance 
with The Cochrane Collaboration principles of System-
atic Reviews and will be reported following the Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses 
(PRISMA) guidelines.15 16
This protocol has been registered with the Interna-
tional Prospective Register of Systematic Reviews (PROS-




All quantitative studies that report anticoagulation strate-
gies for AF, in an adult critical care setting, will be assessed 
for inclusion. Eligible studies will include randomised 
and non- randomised studies.
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Eligible studies must include both a cohort of patients 
with AF who were anticoagulated and a cohort of patients 
with AF who were not anticoagulated. We will include 
studies in patients diagnosed with NOAF (including 
paroxysmal AF) or PEAF (including permanent AF) by 
rhythm classification by continuous ECG monitoring or 
12 lead ECG.
We will include studies conducted in level 2 and level 3 
critical care settings as defined by Marshall et al.17 We will 
include studies enrolling patients from general medical, 
general surgical or mixed mixed/surgical patients.
Phenomenon of interest
Studies must include patients who have been in AF for 
>48 hours, based on the NICE guidelines on initiating 
anticoagulant treatment8 and may include both PEAF 
and NOAF. Studies must describe outcomes associated 
with the chosen anticoagulation strategy including the 
outcomes of interest described below.
Population
Studies that include adult patients admitted to the ICU 
types specified above will be assessed for inclusion. For 
the purpose of this review, an adult is defined as ≥18 years.
Type of intervention and comparator(s)
Interventions
Eligible studies will include any of the following 
treatments:
1. Warfarin.
2. Any other vitamin K antagonist.
3. Unfractionated heparin (UFH).
4. Treatment dose low molecular weight heparin 
(LMWH).
5. Factor Xa inhibitors (eg, Edoxaban, Apixaban, Rivar-
oxaban).
6. Direct thrombin (Factor IIa) inhibitors (Dabigatran, 
Inogatran, Melagatran, Argatroban).
7. Any combination of the above interventions.
Comparators
Comparators will include:
1. Any of the interventions above.
2. Placebo.
3. Standard care where it does not include anticoagulation.
Exclusion criteria
Types of studies
Qualitative studies, case studies, editorials, letters, 
abstract only reports, reviews and commentaries that do 
not include original information will be excluded from 
this review.
Studies of cohorts that have undergone or plan to 
undergo cardiothoracic surgery, permanent pacemaker 
insertion or surgical ablation will be excluded. Studies 
based on service- specific ICUs, for example, cardiac, 
cardiothoracic surgical or neurosurgical units, will be 
excluded in addition to studies based on acute medical 
units or in emergency departments.
Phenomenon of interest
Studies will be excluded if patients have been started on 
any anticoagulation therapy for a reason other than AF 
and cannot be disaggregated from the entire cohort. 
Studies that include patients with an inherited or pre- 
existing bleeding disorder or clotting disorder will also 
be excluded.
Population
Studies of participants under 18 years, pregnant women 
and patients with clear contraindication to anticoagu-
lation therapy, for example, intracranial haemorrhage, 




1. Percentage of patients started on anticoagulation for 
AF (NOAF and/or PEAF) in a critical care setting 
including but not limited to warfarin, LMWH, UFH, 
Factor Xa inhibitors, Factor IIa inhibitors.
Secondary outcome measures
1. Incidence of thromboembolic events (defined as 
stroke, mesenteric ischaemia, acute limb ischaemia, 
pulmonary embolism) during critical care admission 
to identify the outcomes of anticoagulation therapy in 
the critical care setting.
2. Incidence of any in hospital thromboembolic events 
(defined as stroke, mesenteric ischaemia, acute limb 
ischaemia, pulmonary embolism).
3. Development of a major haemorrhage event (defined 
clinically as haemorrhage leading to death, signs of 
shock, requirement for blood transfusion or urgent 
endoscopic / surgical intervention).18
4. ICU length of stay (LOS).
5. ICU mortality.
6. 28- day mortality.
7. 90- day mortality.
8. 365- day mortality.
9. Use of risk stratification scores for anticoagula-
tion decision making (such as CHA2DS2- VASc and 
HASBLED).
10. Severity scores of critical illness (eg, APACHE II and 
SOFA).
Search strategy
We will engage the services of a health information 
specialist, and a comprehensive broad literature search 
will be conducted. Medical subject headings will be used 
to identify papers that matched the search index and rele-
vant selected free text terms will also be used.
The search strategies identified will focus on the 
population (critically ill), the participants (patients with 
AF) and the intervention (any anticoagulation strategy 
mentioned previously). The search strategy will not be 
limited by outcomes studied in order to broaden the 
scope of eligible papers.
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Database searches
We will search the following databases for studies 
published between January 1990 and October 2019;
1. MEDLINE Ovid, Medline Ovid Epub Ahead of Print, 
and Medline Ovid In- Process.
2. EMBASE Ovid.
3. The Cochrane Central Register of Controlled Trials.
4. PUBMED.
5.  ClinicalTrials. gov.
MEDLINE, EMBASE and PUBMED will be access via 
NICE Healthcare Database Advanced Search (HDAS) 
using OpenAthens. We will screen referenced papers 
following full text screening and any review articles identi-
fied during the screening process. We will screen for rele-
vant conference proceedings and include any potentially 
relevant studies. A full description of the search strategy 
that will be used in HDAS (online supplemental file).
Citation management and screening
Results from searches in all databases will be exported 
to Endnote X9 (Clarivate analytics) and duplicates will 
be removed. All citations will be imported into the Covi-
dence systematic review platform (Veritas Health Inno-
vation, Melbourne, Australia).19 Titles and abstracts will 
be screened in duplicate by two independent reviewers 
for relevance to the review and eliminated as appro-
priate. Full text articles that are not excluded after title 
and abstract screening will be screened against the inclu-
sion and exclusion criteria by two independent reviewers. 
Any discrepancies or conflicts in the screening process 
will be resolved by discussion and subsequent input of a 
third reviewer. Primary reason for exclusion will be docu-
mented in Covidence and the screening process will be 
documented in a PRISMA flowchart (figure 1).
Data extraction and management
Data will be extracted in duplicate by two independent 
reviewers using a standardised, prepiloted data extraction 
form.
Information, including the following characteristics, 
will be extracted from studies:
1. Study design and methodology, including title, au-
thors, journal, publication date, study type, study peri-
od and number of participants.
2. All inclusion criteria previously mentioned.
3. Population characteristics, including age, sex, ICU ad-




6. The primary and secondary outcome measures and re-
ported findings of the study.
Any discrepancies within data extraction will be 
resolved through discussion and consultation with a third 
reviewer. We will contact authors if clarification regarding 
the data or methodology is required. If data cannot be 
obtained from the authors, the impact will be discussed 
as a limitation of the review.
Figure 1 PRISMA flowchart of studies selected in the systematic review.
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Risk of bias assessment
Risk of bias will be assessed using a modified Newcastle- 
Ottawa Scale (mNOS), a scoring system for non- 
randomised trials.20 mNOS uses a system by which the 
study is judged on three broad perspectives: the selection 
of the study groups, the comparability and the ascertain-
ment of outcome of interest.
Included randomised controlled trials will be assessed 
with the revised Cochrane Collaborations Risk of Bias 
(RoB 2) tool using the criteria outlined in the Cochrane 
Handbook of Systematic Reviews of Interventions.21 
The RoB 2 tool assesses the following domains: selec-
tion, comparability, outcome performance and will be 
presented in table format.
Data synthesis and analysis
A description of included studies will be reported 
in evidence tables and discussed in the text. We will 
report participant characteristics, interventions, clinical 
outcomes and methodological quality.
Primary outcomes will be reported as the percentage of 
patients that received anticoagulation for any AF (NOAF 
and PEAF) in critical care. If sufficient data allow, we will 
report the percentage of patients started on anticoagula-
tion according to type of AF (NOAF and/or PEAF).
We anticipate that the majority of studies included 
in our systematic review and meta- analysis will be case 
control studies. Therefore, we will present dichotomous 
data as number of participants experiencing the outcome 
with OR and 95% CIs.22 For continuous outcome data, 
we will extract arithmetic means and SD with 95% CIs 
for each outcome, together with the numbers analysed 
in each group. We will also extract medians and ranges 
where provided.
Data from individual studies will be pooled and 
presented visually by Forest plot. We anticipate studies 
to vary significantly; therefore, we will undertake a meta- 
analysis of included studies by using a random effects 
model with 95% CI to estimate pooled estimates of effect. 
We will assess for heterogeneity between studies using the 
Cochran’s Q test and report the degree of heterogeneity 
using the I2 statistic in RevMan (Review Manager, 2014). 
Heterogeneity will be considered low if values are below 
25%, moderated if values are between 25% and 75% and 
high if values are above 75%. Suitability for meta- analysis 
will be determined by the degree of clinical, statistical 
and methodological heterogeneity observed between 
studies. We will explore heterogeneity between studies by 
subgroup analysis assessing a number of factors such as 
study design, intervention and participants. Where there 
is a high degree of heterogeneity (>75%) that cannot be 
explained by clinical or methodological variation, we will 
not undertake a meta- analysis of results. If we are unable 
to pool studies due to heterogeneity, we will describe the 
findings via a narrative synthesis. Meta- analysis will be 
conducted using the Cochrane Collaborations RevMan 
(Review Manager, 2014) software.
We will assess the certainty of our evidence for each 
outcome according to the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
approach.23 GRADE methodology assesses the certainty 
in evidence across the domains of risk of bias, consistency, 
directness, precision and publication bias. The certainty 
of evidence will be reported as high, moderate, low or 
very low.
Subgroup analysis
If we extract sufficient data, we will undertake subgroup 
analysis, assessing the following:
1. Type of anticoagulant therapy.
2. NOAF versus PEAF.
3. Sepsis versus non- sepsis.
4. Illness severity scores (APACHE II score, SOFA score).
5. Risk scores for bleeding and thromboembolic events 
(HASBLED, CHA2DS2- VASc, respectively).
6. Medical versus surgical ICU admission diagnosis.
Patient and public involvement
This protocol will use previously published data. As such, 
there will be no patient and public involvement in the 
design of the study, interpretation of the results. We will 
disseminate the results of this review to any interested 
patients and it will be freely accessible in open access 
journals.
ETHICS AND DISSEMINATION
This proposed systematic review will not include primary 
data and will extract data from published studies; there-
fore, ethical approval is not required. The results of this 
review will be disseminated through publication in clin-
ical specialty journals, including open access journals, 
and various medias including international meetings, 
conferences, congresses and symposiums.
DISCUSSION
This systematic review will assess the evidence available 
for anticoagulation strategies used in the management of 
AF in critically ill patients. AF affects up to 25% of critical 
care admissions, hence the need for systematic evalua-
tion of anticoagulation strategies used in critical care and 
their impact on patient outcomes.24 AF is associated with 
an increased risk of thromboembolic complications, but 
scoring systems used to aid decision making on whether 
and how- to anticoagulate patients with AF have not been 
validated for use in the critical care setting. This review 
will enable a comparison of the anticoagulation strategies 
used for both PEAF and NOAF in critical care and aims 
to assess outcomes including thromboembolic events, 
haemorrhagic events, LOS in critical care and mortality 
on ICU. Critically ill patients have a particularly high risk 
of thromboembolic events, which could theoretically 
be ameliorated by administering anticoagulant therapy 
during critical illness. A limitation of our protocol is that 
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results will not be generalisable to patients who are clini-
cally stable after having been critically ill.
Based on a preliminary search of the literature, we 
believe that this is the first systematic review to consider 
anticoagulation strategies used in the treatment of AF in 
the critically ill patient cohort. We aim for this review to 
provide an evidence base on which recommendations can 
be made, to ultimately reduce the impact of AF on patient 
outcomes during and after critical care admission. We 
will publish the results of this review in clinical specialty 
journals and we present it at international meetings and 
conferences. We will also make our report available via 
our web- based repository and update our PROSPERO 
entry with the web address details.
Twitter Brian Johnston @briwbri
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Supplementary File: Search Strategy used to identify papers included in this review using the Healthcase Databases Advanced 
Search engine.   
DATABASE  MESH TERMS  KEYWORDS (TI AND AB)  
MEDLINE  ANTICOAGULANTS/ OR 
"4HYDROXYCOUMARINS"/ OR  
ABCIXIMAB/ OR ACENOCOUMAROL/  
OR ANCROD/ OR ANTITHROMBINS/  
OR BECAPLERMIN/ OR "BETA 2- 
GLYCOPROTEIN I"/ OR "BLOOD  
COAGULATION FACTOR  
INHIBITORS"/ OR "CITRIC ACID"/ OR  
DALTEPARIN/ OR "DERMATAN  
SULFATE"/ OR DEXTRANS/ OR  
DICUMAROL/ OR "EDETIC ACID"/ OR  
ENOXAPARIN/ OR "ETHYL  
BISCOUMACETATE"/ OR "FIBRIN  
FIBRINOGEN DEGRADATION  
PRODUCTS"/ OR GABEXATE/ OR  
HEPARIN/ OR "HEPARIN, 
LOWMOLECULAR-WEIGHT"/ OR  
HEPARINOIDS/ OR NADROPARIN/ OR  
"PENTOSAN SULFURIC POLYESTER"/  
OR PHENINDIONE/ OR  
PHENPROCOUMON/ OR "PROTEIN  
C"/ OR "PROTEIN S"/ OR "SODIUM  
CITRATE"/ OR TINZAPARIN/ OR  
WARFARIN/ exp "BLOOD  
COAGULATION"/   
(anticoagul* OR anti-coagul* OR warfarin OR heparin* OR 
antiplatelet* OR anti-platelet* OR "Direct Oral Anticoagul*" 
OR "DOAC*" OR "new oral anticoagul*" OR "NOAC*" OR 
apixaban OR dabigatran OR "dabigatran etexilate" OR 













exp "ATRIAL FIBRILLATION"/   
  
  
("atrial fibrillation" OR "AF" OR "atrial flutter*" OR  
"supraventricular tachy*" OR "SVT").ti,ab   
exp "CRITICAL CARE"/   
  
("critical care" OR "Intensive care" OR "ITU" OR "critical* 
ill*" OR "high depend*" OR "intensive therapy").ti,ab   
EMBASE  exp "ANTICOAGULANT AGENT"/   
  
(anticoagul* OR anti-coagul* OR warfarin OR heparin* OR 
antiplatelet* OR anti-platelet* OR "Direct Oral Anticoagul*" 
OR "DOAC*" OR "new oral anticoagul*" OR "NOAC*" OR 
apixaban OR dabigatran OR "dabigatran etexilate" OR 
rivaroxaban OR "vitamin K antagonist*" OR "VKA").ti,ab   
exp "ATRIAL FIBRILLATION"/   
  
("atrial fibrillation" OR "AF" OR "atrial flutter*" OR  
"supraventricular tachy*" OR "SVT").ti,ab   
"INTENSIVE CARE"/   
  
("critical care" OR "Intensive care" OR "ITU" OR "critical* 













  (anticoagul* OR anti-coagul* OR warfarin OR heparin* OR 
antiplatelet* OR anti-platelet* OR "Direct Oral Anticoagul*" 
OR "DOAC*" OR "new oral anticoagul*" OR "NOAC*" OR 
apixaban OR dabigatran OR "dabigatran etexilate" OR 
rivaroxaban OR "vitamin K antagonist*" OR "VKA").ti,ab   
("atrial fibrillation" OR "AF" OR "atrial flutter*" OR  
"supraventricular tachy*" OR "SVT").ti,ab   
("critical care" OR "Intensive care" OR "ITU" OR "critical* 
ill*" OR "high depend*" OR "intensive therapy").ti,ab   
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COCHRANE    (anticoag*)  
   “atrial fibrillation” OR AF  
  
“Critical care” OR “Intensive care” OR “ITU” OR “high 
depend*” OR “HDU”  
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